First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

This study tests combining two targeted drugs — dacomitinib and anlotinib — as a first treatment for patients with advanced non-small cell lung cancer (NSCLC) that has a specific mutation (EGFR L858R). **You may be eligible if...** - You are 18–75 years old - You have advanced or metastatic NSCLC with the EGFR L858R mutation in exon 21 - You have not yet received any systemic treatment for advanced NSCLC - You have measurable disease by imaging - Your performance status is good (ECOG 0–1) - Brain metastases are allowed if stable or controlled **You may NOT be eligible if...** - You have received prior chemotherapy or targeted therapy for advanced NSCLC - You have a different EGFR mutation (not L858R) - Your brain metastases are uncontrolled - Your organ function (liver, kidneys, blood) is inadequate - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.